Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer
CRT with sequential pembrolizumab met criteria for further study. Immunosuppressive changes in the TME differed between arms, reflecting the impact of one dose of pembrolizumab in the concurrent arm.
Authors
- Lazar Vujanović (ORCID: https://orcid.org/0000-0003-1729-8619)
- Heath Devin Skinner (ORCID: https://orcid.org/0000-0003-1836-151X)
- David A. Clump (ORCID: https://orcid.org/0000-0003-3734-9612)
- Gabriel Sica
- Riyue Bao (ORCID: https://orcid.org/0000-0002-6105-1704)
- Dan Paul Zandberg (ORCID: https://orcid.org/0000-0002-1002-8301)
- Brian R. Isett (ORCID: https://orcid.org/0000-0002-1581-0706)
- Raja R. Seethala (ORCID: https://orcid.org/0000-0003-3617-075X)
- James Ohr (ORCID: https://orcid.org/0000-0002-7037-6404)
- Simion I. Chiosea (ORCID: https://orcid.org/0000-0002-5766-8779)
- Julie E. Bauman (ORCID: https://orcid.org/0000-0002-1398-6636)
- Robert L. Ferris (ORCID: https://orcid.org/0000-0001-6605-2071)
- Haiyan Li (ORCID: https://orcid.org/0000-0002-5541-3035)
- Hong Wang (ORCID: https://orcid.org/0000-0002-0209-2899)
Institutions
- West Virginia University (US)
- University of Pittsburgh (US)
- George Washington University (US)
- UPMC Hillman Cancer Center (US)
- UNC Lineberger Comprehensive Cancer Center
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1200/jco-24-01580
- Citations
- 13
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 13.59